Recent Updates
Recently added Catalysts

meningococcal B vaccine & meningococcal ACYW conjugate vaccine

Phase 2

Meningococcal Meningitis, Serogroup A | Vaccines | Infectious Disease |Novartis AG|Trials Updated: Sep 19, 2018

meningococcal B vaccine & meningococcal ACYW conjugate vaccine development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Aug 2009

meningococcal B vaccine & meningococcal ACYW conjugate vaccine target and mechanism

ModalityVaccines

Also known as Meningococcal ACYW vaccine- MenVeo

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment38

FDA Designations

No designations recorded

meningococcal B vaccine & meningococcal ACYW conjugate vaccine clinical trials

meningococcal B vaccine & meningococcal ACYW conjugate vaccine · 1 trial · 5 indications

Phase 2 1
NCT00962624Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy AdultsMeningococcal Meningitis, Serogroup A
COMPLETED38 Analytics
PHASE2COMPLETED
Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults
Meningococcal Meningitis, Serogroup A
NCT0096262438
Unlock trial analytics

Study Endpoints

Primary Endpoints

Proportion of subjects attaining putative protective antibody concentrations against meningococci in the serum bactericidal antibody assay
one month following the last vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION

Interventions

NameTypeDescription
meningococcal B vaccine & meningococcal ACYW conjugate vaccineDRUGMeningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Aged 18-65 years of age * Who have given written informed consent after the nature of the study has been explained. * Who work within the Manchester Medical Microbiology Partnership and may be at potential occupational exposure to meningococci. Exclusion Criteria: * The poss...

Countries:United Kingdom
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Novartis AG (NVS)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with MCompanies A to ZEvery biotech and pharma company we track